Declarations of suspected adverse reactions due to veterinary drugs and vaccines in 2006;Gemeldete unerwünschte Wirkungen von Tierarzneimitteln im Jahr 2006

Schweizer Archiv fur Tierheilkunde

Volumn 149, Issue 10, 2007, Pages 439-448

  Muntener C R ^a,b,e   Bruckner, L ^c   Gassner, B ^b   Sturer A ^d   Demuth, D C ^a   Althaus, F R ^a   Zwahlen, R ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Swissmedic   (Switzerland)

^c INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^d Schweizerisches Toxikologisches Informationszentrum   (Switzerland)

^e Institut fur Veterinarpharmakologie und toxikologie   (Switzerland)

Author keywords

Antiparasitics; Ketamine abuse; Pharmacovigilance; Piroplasmosis vaccine; Stevens Johnson syndrome

Indexed keywords

VACCINE; VETERINARY DRUG;

ANIMAL; ARTICLE; DOMESTIC ANIMAL; DRUG SURVEILLANCE PROGRAM; POSTMARKETING SURVEILLANCE; STANDARD; SWITZERLAND; VETERINARY MEDICINE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; ANIMALS, DOMESTIC; PRODUCT SURVEILLANCE, POSTMARKETING; SWITZERLAND; VACCINES; VETERINARY DRUGS; VETERINARY MEDICINE;

BOS; CANIS FAMILIARIS; EQUIDAE;

EID: 35448977373     PISSN: 00367281     EISSN: None     Source Type: Journal    
DOI: 10.1024/0036-7281.149.10.439     Document Type: Article

References (44)

1. Abe R., Shimizu T, Shibaki A., Nakamura H., Watanabe H., Shimizu H.: Toxic epidermal necrolysis and Stevens-Johnson Syndrome are induced by soluble Fas-ligand. Am. J. Pathol. 2003, 162:1515-1520.
2. Anonym: Missbrauch von Ketamin:neue Modesubstanz der Szene. Deutsches Ärzteblatt. 1999, 96.-A-2724-A2726.
3. Anonym, Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG), SR 812.21.2000.
4. Anonym, Verordnung über die Tierarzneimittel (TAMV), SR 812.212.27, 2004.
5. Blanke Q., Ortigue S., Landis T., Seeck M.: Stimulating illusory own-body perceptions. Nature. 2002, 419:269-270.
6. Bryner J. K., Wang U. K., Hui J. W., Bedodo M., MacDougall C., Anderson I. B.: Dextromethorphan abuse in adolescence: an increasing trend: 1999-2004. Archives of pediatrics & adolescent medicine. 2006, 160:1217-1222.
7. Byrne K. P., Giger, U.: Use of human immunoglobulin for treatment of severe erythema multiforme in a cat. J. Am.Vet. Med. Assoc. 2002, 220:197-201.
8. Dalgarno P.J., Shewan D.: Illicit use of ketamine in Scotland. Journal of psychoactive drugs. 1996, 28:191-199.
9. Domino E. F., Chodoff P., Corssen G.: Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol. Ther. 1965, 6:279-286.
10. Dyer F., Spagnuolo-Weaver M., Tait A.: Suspected adverse reactions, 2005.Vet. Rec. 2006, 158:464-466.
11. EMEA/CVMP/552/03: Guideline on causality assessment for adverse reactions to veterinary medicinal products, 2003.
12. EMEA/CVMP/893/04: Guideline on EU veterinary suspected adverse reaction report form for veterinarians and health professionals, 2005.
13. French L.E.: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol. Int. 2006, 55:9-16.
14. Gough N.: Ketamine: China's Other White Powder. Time Asia online, zugänglich unter http://www.time.com/time/ asia/covers/1101020520/ketamine. html
15. Hirota K., Okawa H., Appadu B., Grandy D., Devi L., Lambert D.: Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology. 1999, 90: 174-182.
16. Ito K., Hara H., Okada T., Shimojima H., Suzuki H.; Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fasligand expression. Clin. Exp. Dermatol. 2004, 29:679-680.
17. Jansen K. L.: Ketamine - can chronic use impair memory? Int J Addict. 1990, 25:133-139.
18. Jansen K. L. R.: A review of the nonmedical use of ketamine: use,users and consequences.J.Psychoactive Drugs. 2000, 32: 419-433.
19. Klepstad P., Borchgrevink P. C.: Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta anaesthesiologica Scandinavica. 1997, 41:422-426.
20. La Grenade L., Lee L., Weaver J., Bonnel R., Karwoski C, Governale L., Brinker A.: Comparison of reporting of StevensJohnson syndrome and toxic epidermal necrolysis in assodation with selective COX-2 inhibitors. Drug Saf. 2005 28: 917-924.
21. Littlewood C. L., Jones N., O'Neill M.J., Mitchell S. N., Tricklebank M., Williams S. C.: Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl). 2006, 186:64-81.
22. Lyell A.: A toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J. Dermatol. 1956, 68:355-361.
23. Matsuki A., Ishihara H., Kotani N, Sakai T., Hirota K., Muraoka M., Hashimoto H., Tsubo T, Takahashi S., Koh H., Wakayama S., Sato Y., Nagao H.: A clinical study of total intravenous anesthesia by using mainly propofol, fentanyl and ketamine -with special reference to its safety based on 26,079 cases. Masui. 2002, 51:1336-1342.
24. Miller S. C.: Dextromethorphan psychosis, dependence and physical withdrawal. Addict. Biol. 2005, 10:325-327.
25. Moore N. N, Bostwick J. M.: Ketamine dependence in anesthesia providers. Psychosomatics. 1999, 40:356-359.
26. Müntener C. R., Gassner B., Demuth D. G., Althaus E R., Zwahlen R.: Pharmacovigilance für Tierarzneimittel in der Schweiz. Schweiz. Arch. Tierheilk. 2004, 146:499-505.
27. Müntener C. R., Gassner B., Demuth D. C., Althaus E R., Zwahlen R.: Meldungen zu unerwünschten Wirkungen von Tierarzneimitteln im Jahr 2004. Schweiz. Arch. Tierheilk. 2005, 147:304-310.
28. Müntener C. R., Bruckner L., Gassner B., Demuth D. C., Althaus F. R., Zwahlen R.: Gemeldete unerwünschte Wirkungen von Tierarzneimitteln im Jahr 2005. Schweiz. Arch. Tierheilk. 2007, 149:57-63.
29. Nishimura M., Sato K., Okada T., Yoshiya, I., Schloss P., Shimada S., Tohyama M.: Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology. 1998, 887:768-774.
30. Nuttall T. J., Malham T: Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. J. Small Anim. Pract. 2004, 45:357-361
31. Paul C., Wolkenstein P., Adle H., Wechsler J., Garchon H.J., Revuz J., Roujeau J. C.: Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br. J. Dermatol. 1996, 134:710-714.
32. Schwartz R. H.: Adolescent abuse of dextromethorphan. Clinical pediatrics. 2005, 44:565-568.
33. Scott D. W., Miller W. H.: Idiosyncratic cutaneous adverse drug reactions in the dog: literature review and report of 101 cases. Canine Practice. 1999, 24:16-22.
34. Scott D. W., Miller W. H.: Erythema multiforme in dogs and cats: literature review and case material from the Cornell University College of veterinary Medicine (1988-96). Vet. Dermatol. 1999, 10:297-309.
35. Scott D. W., Miller W. H., Griffin C. E.: Immunologic skin diseases. In: Muller & Kirk's Small animal dermatology, 5th edition. Hrsg. WB. Saunders Company, Philadelphia, London. 1995, 596-602.
36. Siegel R. K.: Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Phencyclidine abuse: an appraisal. Hrsg. Peterson R. C. und Stillman R. C., National Institute of Drug Abuse, Rockville, MD, USA, 1978
37. Smith G. S., Schloesser R., Brodie J. D., Dewey S. L., Logan J., Vitkun S.A., Simkowitz P., Hurley A., Cooper T.: Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11 C-raclopride in normal human subjects. Neuropsychopharmacology. 1997, 18: 18-25.
38. Stevens A. M., Johnson F. C.: A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am. J. Dis. Child. 1922, 24:526-533.
39. Swissmedic: Sofortiger Vertriebsstopp für Bextra® Filmtabletten, 7.April 2005. Zugänglich unter www.swissmedic.ch
40. Weiner A. L., Vieira L., McKay C.A., Bayer M.J.: Ketamine abusers presenting to the emergency department: a case series. J. Emerg. Med. 2000, 18:447-451.
41. Wolff K., Winstock A. R.: Ketamine. From medicine to misuse. CNS Drugs 2006, 20:199-218.
42. Wolkenstein P., Charue D., Laurent P., Revuz J., Roujeau J. C., Bagot M.: Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch. Dermatol. 1995, 131:544-551.
43. Wood P.L.: The NMDA receptor complex: a long and winding road to therapeutics. IDrugs 2005, 8:229-235.
44. Zarate C.A., Singh J. B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D. S., Manji H. K.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006 63:856-864.